Drug Profile
PUR 5700
Alternative Names: PUR-5700; RV-7031Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator RespiVert
- Developer Pulmatrix
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
- 28 May 2023 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation)
- 28 May 2023 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Inhalation)